PETALING JAYA: Duopharma Biotech Bhd’s recent win for the supply of Insugen will contribute positively to the group’s earnings over the next three years.
Assuming a profit after tax margin of 5%, the contract is estimated to contribute about RM6.25mil (previously about RM4mil) per annum in net earnings.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!